ACHV
Achieve Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$6.58
−8.48%Oct 21, 2026, 12:30 UTC
ACHIEVE LIFE SCIENCES, INC. announced positive 52-week efficacy results from its open-label ACHIEVE LIFE SCIENCES, INC. trial of cytisinicline for smoking and vaping cessation, reporting that nearly one-third of participants still smoking or vaping after a prior ACHIEVE LIFE SCIENCES, INC. trial had quit by the end of treatment and that 39% of participants whose prior attempt used placebo had quit.
Source:Oct 6, 2026, 20:02 UTC
ACHIEVE LIFE SCIENCES, INC. announced inducement equity awards for four new employees, comprising options for 46,500 shares and restricted stock units covering 44,500 shares, and awards for newly appointed CFO Benjamin Halladay comprising an option for up to 200,000 shares and 200,000 restricted stock units.
Source:Oct 1, 2026, 20:58 UTC
Achieve Life Sciences, Inc. appointed Benjamin Halladay as Chief Financial Officer and principal financial officer, effective October 5, 2026.
Sep 30, 2026, 14:15 UTC
Achieve Life Sciences shares rose 4.94% to $8.07 after an analyst initiated coverage with a Buy rating and an $18 price target.
Source:Sep 28, 2026, 12:30 UTC
Achieve Life Sciences announced that new 52-week cytisinicline efficacy data for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026 in Phoenix, Arizona, October 18-21.
Source:Sep 3, 2026, 21:15 UTC
Achieve Life Sciences granted new hire inducement stock options for 315,000 shares and RSUs for 283,000 shares to seven new employees under its 2024 Equity Inducement Plan.
Source:Jul 31, 2026, 12:30 UTC
Achieve Life Sciences announced that its board approved granting stock options for 1,190,000 shares and RSUs for 125,000 shares of common stock to six new employees under its 2024 Equity Inducement Plan.
Source:Jun 22, 2026, 12:30 UTC
Achieve Life Sciences received a Complete Response Letter from the FDA for its cytisinicline NDA, citing manufacturing deficiencies at a third-party facility and incomplete labeling.
Jun 2, 2026, 00:00 UTC
Achieve Life Sciences appointed Jeff Farrow and Reid Waldman, M.D. as directors, effective May 29, 2026, each receiving stock options to purchase 47,250 shares vesting monthly over three years.